Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 19/20 | 0.73 |
| ▸ | CHUK | O15111 | 5/20 | 0.56 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620938 | 0.92 | IKBKB (0.62) | IKBKBCHUKCAMKK2BTKCSF1R | |
| SCHEMBL621424 | 0.91 | IKBKB (0.72) | IKBKBCHUKCAMKK2BTKCSF1R | |
| SCHEMBL619129 | 0.89 | IKBKB (0.77) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621371 | 0.89 | IKBKB (0.80) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL620634 | 0.87 | IKBKB (0.77) | IKBKBCHUKCAMKK2BTKCSF1R | |
| SCHEMBL621428 | 0.87 | IKBKB (0.60) | IKBKBCHUKCAMKK2BTKCSF1R | |
| SCHEMBL621580 | 0.86 | IKBKB (0.76) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL620211 | 0.85 | IKBKB (0.68) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL621776 | 0.85 | IKBKB (0.68) | IKBKBCHUKBTKCSF1RAURKA | |
| SCHEMBL620230 | 0.85 | IKBKB (1.00) | IKBKBCHUKBTKCSF1RAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372875-B2 | Indole carboxamides as IKK2 inhibitors | GlaxoSmithKline, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2012-02-16 | — | — | US | disclosed |
| US-8071584-B2 | Indole carboxamides as IKK2 inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | GLAXOSMITHKLINE LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040958-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | IKBKB 8/4885CHUK 14/4885CAMKK2 209/4885 |
| US-20100130468-A1 | INDOLE CARBOXAMIDES AS IKK2 INHIBITORS | IDO2, IDO1, NFKBIA | IKBKB 8/4885CHUK 14/4885CAMKK2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.